New Pre-Clinical Data for Iclaprim

Motif Bio Presents New Pre-Clinical Data for Iclaprim at IDWeek 2017™

https://globenewswire.com/news-release/2017/10/06/1142163/0/en/Motif-Bio-Presents-New-Pre-Clinical-Data-for-Iclaprim-at-IDWeek-2017.html

1. Pre-Clinical Data Support the Potential Use of Iclaprim in the Treatment of Staphylococcus aureus Pneumonia in Cystic Continue reading New Pre-Clinical Data for Iclaprim

Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

Xconomy Texas Austin — A year after releasing results from a Phase 2 clinical trial, Savara Pharmaceuticals has announced $20 million in Series C funding that it will use to take its inhaled version of an antibiotic to Phase 3.

Continue reading Austin Biotech Savara Nets $20M in Series C for Phase 3 Study

New therapeutic options for respiratory tract infections.

PURPOSE OF REVIEW:
The progressive increase of respiratory tract infections caused by multidrug-resistant organisms (MDROs) has been associated with delays in the prescription of an adequate antibiotic treatment and increased mortality, Continue reading New therapeutic options for respiratory tract infections.